PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy.
Pottayil G. Sasikumar,Naremaddepalli S. Sudarshan,Sreenivas Adurthi,Raghuveer Ramachandra,Dodderi S. Samiulla,Anirudha Lakshminarasimhan,Anuradha Ramanathan,Talapaneni Chandrasekhar,Amit A. Dhudashiya,Sumalatha Rani Talapati,Nagesh Gowda,Sreenivasulareddy Palakolanu,Jiju Mani,Bandi Srinivasrao,David Joseph,Nigam Kumar,Rashmi Nair,Hanudatta S. Atreya,Nagaraj Gowda,Murali Ramachandra +19 more
- Vol. 4, Iss: 1, pp 699-699
Reads0
Chats0
TLDR
CA-170 as mentioned in this paper is an amino acid inspired small molecule inhibitor of PD-L1 and VISTA derived from the interface of the PD-1 and PD-l1.Abstract:
Small molecule immune checkpoint inhibitors targeting PD-1 and other pathways may offer advantages including ease of dosing, ability to manage immune-related adverse events (irAEs) due to their shorter pharmacokinetic exposure and opportunity to target more than one pathway for improving efficacy. Here we describe the identification and characterization of CA-170, an amino acid inspired small molecule inhibitor of PD-L1 and VISTA derived from the interface of PD-1 and PD-L1. CA-170 exhibited potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes. Observed blocking of PD-L1 signaling and binding to PD-L1 in the cellular context without preventing the assembly of PD-1:PD-L1 complex support the formation of a defective ternary complex as the mechanism of action of CA-170. Oral administration of CA-170 resulted in increased proliferation and activation of T cells in the tumor, and significant anti-tumor efficacy in a number of immunocompetent mouse tumor models either as a single agent or in combination with approved therapeutics. These results prompted the advancement of CA-170 to human clinical trials.read more
Citations
More filters
Journal ArticleDOI
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
TL;DR: The authors review the transcriptional, post- transcriptional and translational regulation of PD-L1 expression in cancers as well as the diverse post-translational modifications, including phosphorylation, palmitoylation, glycosylation, acetylation and ubiquitination, that affect PD- L1 stability and activity.
Journal ArticleDOI
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Yuchen Wang,Hao Zhang,Chao Liu,Zeyu Wang,Wantao Wu,Nan Zhang,Hong Zhang,Jason Hu,Peng Luo,Jian Zhang,Zao-bin Liu,Yun Peng,Zhixiong Liu,Lanhua Tang,Quan Cheng +14 more
TL;DR: A comprehensive review of immune checkpoint inhibitors can be found in this article , where the authors systematically summarized and discussed these molecules' biological structures, molecular features, and the corresponding targeted drugs, aiming to help the in-depth understanding of immune checkpoints and promote the clinical practice of ICI therapy.
Journal ArticleDOI
Cancer immunotherapy by immune checkpoint blockade and its advanced application using bio-nanomaterials.
TL;DR: In this article , the authors discuss the use of nanoparticles as carriers for delivering immune checkpoint inhibitors and their efficacy in cancer combination therapy and discuss their fundamental and physiochemical properties depend on various cancer therapeutic strategies such as chemotherapeutics, nucleic acid-based treatments, photothermal therapy, and photodynamic agents.
Journal ArticleDOI
The expanding role for small molecules in immuno-oncology
TL;DR: The recent milestones and hurdles encountered in small-molecule immuno-oncology drugs that address intracellular pathways are discussed, as well as the views on the best path forward.
Journal ArticleDOI
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
TL;DR: The future of immunotherapy in lung cancer continues to hold promise with the development of combination therapies, cytokine modulating therapies and cellular therapies, and innovative advances in technology, such as artificial intelligence and machine learning, will begin to play a role in the future care of patients with lung cancer.
References
More filters
Journal ArticleDOI
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer,Scott N. Gettinger,David Smith,David F. McDermott,John D. Powderly,Richard D. Carvajal,Jeffrey A. Sosman,Michael B. Atkins,Philip D. Leming,David R. Spigel,Scott J. Antonia,Leora Horn,Charles G. Drake,Drew M. Pardoll,Lieping Chen,William H. Sharfman,Robert A. Anders,Janis M. Taube,Tracee L. McMiller,Haiying Xu,Alan J. Korman,Maria Jure-Kunkel,Shruti Agrawal,Dan McDonald,Georgia Kollia,Ashok Kumar Gupta,Jon M. Wigginton,Mario Sznol +29 more
TL;DR: Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
Journal ArticleDOI
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer,Scott S. Tykodi,Scott S. Tykodi,Laura Q.M. Chow,Wen-Jen Hwu,Suzanne L. Topalian,Patrick Hwu,Charles G. Drake,Luis H. Camacho,John S. Kauh,Kunle Odunsi,Henry C. Pitot,Omid Hamid,Shailender Bhatia,Renato G. Martins,Keith D. Eaton,Shuming Chen,Theresa M. Salay,Suresh Alaparthy,Joseph F. Grosso,Alan J. Korman,Susan M. Parker,Shruti Agrawal,Stacie M. Goldberg,Drew M. Pardoll,Ashok Kumar Gupta,Jon M. Wigginton +26 more
TL;DR: Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Journal ArticleDOI
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer,Charles G. Drake,Ira Wollner,John D. Powderly,Joel Picus,William H. Sharfman,Elizabeth Stankevich,Alice Pons,Theresa M. Salay,Tracee L. McMiller,Marta M. Gilson,Changyu Wang,Mark J. Selby,Janis M. Taube,Robert A. Anders,Lieping Chen,Alan J. Korman,Drew M. Pardoll,Israel Lowy,Suzanne L. Topalian +19 more
TL;DR: Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity, and tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment.
Journal ArticleDOI
The B7–CD28 superfamily
TL;DR: The current understanding of the new members of the B7 and CD28 families is summarized, their therapeutic potential is discussed, and other immunoregulatory pathways remain to be described.
Journal ArticleDOI
Surface chromium on Terracotta Army bronze weapons is neither an ancient anti-rust treatment nor the reason for their good preservation
Marcos Martinón-Torres,Xiuzhen Li,Yin Xia,Agnese Benzonelli,Andrew Bevan,Shengtao Ma,Jianhua Huang,Liang Wang,Desheng Lan,Jiangwei Liu,Siran Liu,Zhen Zhao,Kun Zhao,Thilo Rehren,Thilo Rehren +14 more
TL;DR: It is shown that the lacquer used to cover warriors and certain parts of weapons is rich in chromium, and it is demonstrated that chromium on the metals is contamination from nearby lacquer after burial, and the chromium anti-rust treatment theory should be abandoned.